logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2017: One in four small and early-stage breast cancers can be aggressive and benefit from adjuvant chemotherapy

Clinical risk assessment for recurrence and metastasis is not enough to avoid adjuvant chemotherapy. Genomic assessment can help to identify those at higher risk that benefit from treatments.